Regression of intracranial meningioma following treatment with nivolumab: Case report and review of the literature

Efrat Gelerstein, Assaf Berger, Tali Jonas-Kimchi, Ido Strauss, Andrew A. Kanner, Deborah T. Blumenthal, Maya Gottfried, Nevo Margalit, Zvi Ram, Tal Shahar

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

The treatment of refractory meningiomas remains a challenge for both neurosurgeons and neuro-oncologists. There have been no clinical reports of the use or effects of anti-PD-1 therapy in patients with meningioma. We describe a patient whose intracranial meningioma decreased significantly in size after treatment with nivolumab, a monoclonal antibody targeting PD-1, for a concomitant advanced lung cancer. This is the first clinical report suggesting that antibodies targeting PD-1 are effective in treating meningioma. It should encourage further research into the use of checkpoint inhibitors in meningioma.

Original languageEnglish
Pages (from-to)51-53
Number of pages3
JournalJournal of Clinical Neuroscience
Volume37
DOIs
StatePublished - 1 Mar 2017
Externally publishedYes

Keywords

  • Anti-PD-1
  • Brain tumor
  • Checkpoint inhibitor
  • Meningioma
  • Nivolumab

Fingerprint

Dive into the research topics of 'Regression of intracranial meningioma following treatment with nivolumab: Case report and review of the literature'. Together they form a unique fingerprint.

Cite this